- Home
- STOK
as 12-17-2024 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 721.4M | IPO Year: | 2019 |
| Target Price: | $21.40 | AVG Volume (30 days): | 562.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.09 - $17.58 | Next Earning Date: | 11-05-2024 |
| Revenue: | $16,742,999 | Revenue Growth: | 81.08% |
| Revenue Growth (this year): | 103.04% | Revenue Growth (next year): | -10.90% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 9 '24 | Sell | $12.99 | 2,586 | $33,595.50 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 9 '24 | Sell | $12.99 | 6,786 | $88,158.28 | 61,885 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 6 '24 | Sell | $12.78 | 13,945 | $178,182.24 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 6 '24 | Sell | $12.78 | 6,170 | $78,837.18 | 61,885 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 1 '24 | Sell | $12.07 | 10,000 | $120,698.00 | 44,746 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Nov 1 '24 | Sell | $12.68 | 10,000 | $126,803.00 | 44,746 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Oct 1 '24 | Sell | $12.06 | 10,000 | $120,648.00 | 44,746 | |
| Skorpios Trust | STOK | 10% Owner | Sep 19 '24 | Sell | $14.05 | 1,937,500 | $27,221,875.00 | 8,906,181 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
MT Newswires
12 days ago
Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient
Business Wire
12 days ago
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Zacks
13 days ago
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
MT Newswires
14 days ago
Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome
Business Wire
14 days ago
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
Business Wire
16 days ago
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
Pharma Voice
22 days ago
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.